Literature DB >> 20721924

A comparison of two brief screening measures of cognitive impairment in Huntington's disease.

Laura Mickes1, Mark Jacobson, Guerry Peavy, John T Wixted, Stephanie Lessig, Jody L Goldstein, Jody Corey-Bloom.   

Abstract

The goal of this study was to explore whether the Montreal Cognitive Assessment (MoCA), a new screening instrument, would be more sensitive to mild to moderate cognitive impairment in Huntington's disease (HD) than an established screening measure, the Mini Mental State Exam (MMSE). Our reasoning for this query is that the MoCA includes a broader range of test items and an additional assessment of executive functioning and attention compared with the MMSE. Using the receiver operating characteristic (ROC) analysis to examine performance of HD and control groups on both tests on overall scores and scores from various subdomains (i.e., visuospatial abilities) revealed that the MoCA achieved higher sensitivity without sacrificing specificity in many domains relative to the MMSE.

Entities:  

Mesh:

Year:  2010        PMID: 20721924     DOI: 10.1002/mds.23181

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  11 in total

1.  Evaluating cognition in individuals with Huntington disease: Neuro-QoL cognitive functioning measures.

Authors:  Jin-Shei Lai; Siera Goodnight; Nancy R Downing; Rebecca E Ready; Jane S Paulsen; Anna L Kratz; Julie C Stout; Michael K McCormack; David Cella; Christopher Ross; Jenna Russell; Noelle E Carlozzi
Journal:  Qual Life Res       Date:  2017-12-08       Impact factor: 4.147

Review 2.  Cognitive impairment in Huntington disease: diagnosis and treatment.

Authors:  Jane S Paulsen
Journal:  Curr Neurol Neurosci Rep       Date:  2011-10       Impact factor: 5.081

3.  Usefulness of the Montreal Cognitive Assessment (MoCA) in Huntington's disease.

Authors:  Shea Gluhm; Jody Goldstein; Daniel Brown; Charles Van Liew; Paul E Gilbert; Jody Corey-Bloom
Journal:  Mov Disord       Date:  2013-06-24       Impact factor: 10.338

4.  Clinical severity of Huntington's disease does not always correlate with neuropathologic stage.

Authors:  Jagan A Pillai; Lawrence A Hansen; Eliezer Masliah; Jody L Goldstein; Steven D Edland; Jody Corey-Bloom
Journal:  Mov Disord       Date:  2012-06-01       Impact factor: 10.338

5.  Normative Data for the Montreal Cognitive Assessment in Middle-Aged and Elderly Quebec-French People.

Authors:  Eddy Larouche; Marie-Pier Tremblay; Olivier Potvin; Sophie Laforest; David Bergeron; Robert Laforce; Laura Monetta; Linda Boucher; Pascale Tremblay; Sylvie Belleville; Dominique Lorrain; Jean-François Gagnon; Nadia Gosselin; Christian-Alexandre Castellano; Stephen C Cunnane; Joël Macoir; Carol Hudon
Journal:  Arch Clin Neuropsychol       Date:  2016-11-22       Impact factor: 2.813

6.  Cognitive performance on the mini-mental state examination and the montreal cognitive assessment across the healthy adult lifespan.

Authors:  Shea Gluhm; Jody Goldstein; Kiet Loc; Alexandra Colt; Charles Van Liew; Jody Corey-Bloom
Journal:  Cogn Behav Neurol       Date:  2013-03       Impact factor: 1.600

7.  Concordance of the Montreal cognitive assessment with standard neuropsychological measures.

Authors:  Sally J Vogel; Sarah J Banks; Jeffrey L Cummings; Justin B Miller
Journal:  Alzheimers Dement (Amst)       Date:  2015-06-28

8.  Canadian academy of geriatric psychiatry survey of brief cognitive screening instruments.

Authors:  Zahinoor Ismail; Benoit H Mulsant; Nathan Herrmann; Mark Rapoport; Magnus Nilsson; Ken Shulman
Journal:  Can Geriatr J       Date:  2013-06-03

9.  Using the Montreal Cognitive Assessment Scale to screen for dementia in Chinese patients with Parkinson's Disease.

Authors:  Ling Chen; Cuiyu Yu; Xiaosu Fu; Weiguo Liu; Ping Hua; Ning Zhang; Shenghan Kuo
Journal:  Shanghai Arch Psychiatry       Date:  2013-10

10.  Comparison of cognitive and UHDRS measures in monitoring disease progression in Huntington's disease: a 12-month longitudinal study.

Authors:  Eng A Toh; Michael R MacAskill; John C Dalrymple-Alford; Daniel J Myall; Leslie Livingston; Sandy Ad Macleod; Tim J Anderson
Journal:  Transl Neurodegener       Date:  2014-07-12       Impact factor: 8.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.